These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35305260)

  • 1. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
    Merola JF; McInnes IB; Deodhar AA; Dey AK; Adamstein NH; Quebe-Fehling E; Aassi M; Peine M; Mehta NN
    Rheumatol Ther; 2022 Jun; 9(3):935-955. PubMed ID: 35305260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
    Dougados M; Kiltz U; Kivitz A; Pavelka K; Rohrer S; McCreddin S; Quebe-Fehling E; Porter B; Talloczy Z
    Rheumatol Int; 2022 Feb; 42(2):205-213. PubMed ID: 34773130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
    Feist E; Baraliakos X; Behrens F; Thaçi D; Plenske A; Klaus P; Meng T
    Rheumatol Ther; 2024 Apr; 11(2):331-348. PubMed ID: 38308727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
    Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
    Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
    Gerdes S; Pinter A; Papavassilis C; Reinhardt M
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):533-541. PubMed ID: 31599476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.
    Gaffney K; Gullick N; MacKay K; Patel Y; Sengupta R; Sheeran T; Hemmings L; Pamies P
    Rheumatol Adv Pract; 2023; 7(3):rkad055. PubMed ID: 37663578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis-a
    Dehlin M; Fasth AER; Reinhardt M; Jacobsson LTH
    Rheumatol Adv Pract; 2021; 5(1):rkab009. PubMed ID: 33748660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.
    Ogdie A; Gladman DD; Coates LC; Pournara E; Parikh B; Mease PJ
    Rheumatol Ther; 2023 Aug; 10(4):849-860. PubMed ID: 37148474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
    Kivitz AJ; Kremer JM; Legerton CW; Pricop L; Singhal A
    Rheumatol Ther; 2024 Jun; 11(3):675-689. PubMed ID: 38625671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.
    Houghton K; Patil D; Gomez B; Feldman SR
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1373-1384. PubMed ID: 34110605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
    Deodhar A; Gladman DD; McInnes IB; Spindeldreher S; Martin R; Pricop L; Porter B; Safi J; Shete A; Bruin G
    J Rheumatol; 2020 Apr; 47(4):539-547. PubMed ID: 31203228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy.
    Cortesi PA; Fornari C; Gisondi P; Iannone F; Antonazzo IC; Aloisi E; Fiocchi M; Ritrovato D; Mantovani LG
    Pharmacoecon Open; 2023 May; 7(3):405-416. PubMed ID: 36929647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Healthcare Resource Utilization Among Newly Diagnosed Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, and Hidradenitis Suppurativa Patients with Past Diagnosis of an Inflammatory Condition: A Retrospective Cohort Analysis of Claims Data in the United States.
    Hopson S; Gibbs LR; Syed S; Low R; McClung L; Beaty S
    Adv Ther; 2023 Oct; 40(10):4358-4376. PubMed ID: 37486558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.
    Kircik L; Fowler J; Weiss J; Meng X; Guana A; Nyirady J
    Dermatol Ther (Heidelb); 2016 Dec; 6(4):627-638. PubMed ID: 27573260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.
    Menter A; Cather JC; Jarratt M; Meng X; Guana A; Nyirady J
    Dermatol Ther (Heidelb); 2016 Dec; 6(4):639-647. PubMed ID: 27576559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
    Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
    Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.